Press release
Psoriasis Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis | Mylan, Biocad, Bristol-Myers Squibb, Celltrion, Coherus BioSciences, Janssen Pharmaceuticals, Can-Fite Bio
Psoriasis Pipeline Insights
Psoriasis Overview:
Psoriasis is a chronic inflammatory skin condition that presents with various clinical symptoms and is caused by a combination of genetic, environmental, and immune system factors. It is a non-contagious skin disorder that affects nearly 2% of the global population. The extent of skin involvement can vary from person to person, with cases ranging from mild (10%) psoriasis. The most commonly seen form is chronic plaque psoriasis, also known as psoriasis vulgaris. This disorder involves the activation of dendritic cells, T lymphocytes, macrophages, neutrophils, and keratinocytes, leading to the development of skin lesions. Topical treatments are the standard approach for managing mild to moderate psoriasis.
Request for a detailed insights report on Psoriasis pipeline insights @ https://www.delveinsight.com/report-store/psoriasis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
"Psoriasis Pipeline Insight 2024" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Psoriasis Therapeutics Market.
Key Takeaways from the Psoriasis Pipeline Report
DelveInsight's Psoriasis pipeline report depicts a robust space with 80+ active players working to develop 80+ pipeline therapies for Psoriasis treatment.
In October 2023, the FDA approved BIMZELX (bimekizumab-bkzx) for treating moderate to severe psoriasis in adults who are suitable candidates for systemic therapy or phototherapy. It is the first and only inhibitor of both IL-17A and IL-17F approved for treating adults with moderate to severe plaque psoriasis.
In October 2023, Arcutis Biotherapeutics announced that the FDA had approved a supplemental new drug application (sNDA) to expand the use of ZORYVE (roflumilast) cream 0.3% for topical treatment of plaque psoriasis, including areas with skin folds, for children aged 6 to 11 years.
In November 2020, Biohaven Pharmaceutical partnered with Weill Cornell Medicine to launch a clinical trial using a Biohaven CGRP-receptor antagonist for treating plaque psoriasis. CGRP, a neuropeptide, is thought to play a key role in the development of inflammatory skin conditions like psoriasis.
Key Psoriasis companies such as Mylan, Biocad, Bristol-Myers Squibb, Celltrion, Coherus BioSciences, Janssen Pharmaceuticals, Can-Fite Biopharma, Arcutis Biotherapeutics, Amgen, Iltoo Pharma, GlaxoSmithKline, Galectin Therapeutics, Evelo Biosciences, Galderma, BioMimetix JV, Menlo Therapeutics Inc., Aristea Therapeutics, UNION Therapeutics, MetrioPharm, Sienna Biopharmaceuticals, and others are evaluating new drugs for Psoriasis to improve the treatment landscape.
Promising Psoriasis pipeline therapies in various stages of development include Topical roflumilast, GSK2982772, and others.
Psoriasis Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the key companies that are developing therapies in the Psoriasis Market.
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Psoriasis treatment.
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Psoriasis market.
Download our free sample page report on Psoriasis pipeline insights @ https://www.delveinsight.com/sample-request/psoriasis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Psoriasis Emerging Drugs
Topical roflumilast: Arcutis Biotherapeutics
GSK2982772: GlaxoSmithKline
Psoriasis Companies
Over 80 major companies are working on developing therapies for psoriasis. Among them, Biocad has psoriasis drug candidates in the most advanced stage, namely, registered.
DelveInsight's report covers around 80+ products under different phases of clinical development like
Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Psoriasis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Intravenous
Subcutaneous
Oral
Intramuscular
Psoriasis Products have been categorized under various Molecule types such as
Monoclonal antibody
Small molecule
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging Psoriasis Therapies and Key Companies: Psoriasis Clinical Trials and advancements @ https://www.delveinsight.com/report-store/psoriasis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Psoriasis Pipeline Therapeutic Assessment
• Psoriasis Assessment by Product Type
• Psoriasis By Stage
• Psoriasis Assessment by Route of Administration
• Psoriasis Assessment by Molecule Type
Download Psoriasis Sample report to know in detail about the Psoriasis treatment market @ Psoriasis Therapeutic Assessment @ https://www.delveinsight.com/sample-request/psoriasis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Table of Content
1. Report Introduction
2. Executive Summary
3. Psoriasis Current Treatment Patterns
4. Psoriasis - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Psoriasis Late-Stage Products (Phase-III)
7. Psoriasis Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Psoriasis Discontinued Products
13. Psoriasis Product Profiles
14. Psoriasis Key Companies
15. Psoriasis Key Products
16. Dormant and Discontinued Products
17. Psoriasis Unmet Needs
18. Psoriasis Future Perspectives
19. Psoriasis Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights About the Psoriasis Pipeline Reports Offerings: https://www.delveinsight.com/report-store/psoriasis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Contact Info:
Kritika Rehani
krehani@delveinsight.com
info@delveinsight.com
+14699457679
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Psoriasis Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis | Mylan, Biocad, Bristol-Myers Squibb, Celltrion, Coherus BioSciences, Janssen Pharmaceuticals, Can-Fite Bio here
News-ID: 3865672 • Views: …
More Releases from DelveInsight Business Research LLP
Urinary Tract Obstruction Treatment Devices Market Dynamics 2032: Research Trend …
DelveInsight's Urinary Tract Obstruction Treatment Devices Market Insights Report 2032 provides the current and forecast market analysis, individual leading Urinary Tract Obstruction Treatment Devices Companies market shares, challenges, Urinary Tract Obstruction Treatment Devices Market Drivers, barriers, trends, and key market Urinary Tract Obstruction Treatment Devices companies in the market.
To read more about the latest highlights related to the Urinary Tract Obstruction Treatment Devices Market, get a snapshot of the key…
DelveInsight's Portable Ultrasound Bladder Scanner Market Report 2032: In-Depth …
DelveInsight's Portable Ultrasound Bladder Scanner Market Insights Report 2032 provides the current and forecast market analysis, individual leading Portable Ultrasound Bladder Scanner Companies market shares, challenges, Portable Ultrasound Bladder Scanner Market Drivers, barriers, trends, and key market Portable Ultrasound Bladder Scanner companies in the market.
To read more about the latest highlights related to the Portable Ultrasound Bladder Scanner Market, get a snapshot of the key highlights entailed in the Market…
Disposable Endoscopes Market Report 2032: Key Market Drivers, Competitive Landsc …
DelveInsight's Disposable Endoscopes Market Insights Report 2032 provides the current and forecast market analysis, individual leading Disposable Endoscopes Companies market shares, challenges, Disposable Endoscopes Market Drivers, barriers, trends, and key market Disposable Endoscopes companies in the market.
To read more about the latest highlights related to the Disposable Endoscopes Market, get a snapshot of the key highlights entailed in the Market Report @ Disposable Endoscopes Market Size- https://www.delveinsight.com/sample-request/disposable-endoscopes-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from…
DelveInsight's Comprehensive Analysis of the Venous Thromboembolism Treatment De …
DelveInsight's Venous Thromboembolism Treatment Devices Market Insights Report 2032 provides the current and forecast market analysis, individual leading Venous Thromboembolism Treatment Devices Companies market shares, challenges, Venous Thromboembolism Treatment Devices Market Drivers, barriers, trends, and key market Venous Thromboembolism Treatment Devices companies in the market.
To read more about the latest highlights related to the Venous Thromboembolism Treatment Devices Market, get a snapshot of the key highlights entailed in the Market…
More Releases for Psoriasis
Prevalence Of Psoriasis Driving Market Growth: A Key Catalyst Accelerating Psori …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Psoriasis Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
Over the recent years, there has been a robust growth in the size of the psoriasis market. It is estimated to rise from $26.45 billion in 2024 to $28.93 billion in 2025, with a compound annual…
Psoriasis Vulgaris Market
Introduction
Psoriasis vulgaris, also known as plaque psoriasis, is the most common form of psoriasis, accounting for nearly 80-90% of all cases. It is a chronic autoimmune condition marked by red, scaly plaques that can cause significant physical discomfort and emotional distress. Affecting millions worldwide, psoriasis vulgaris is increasingly recognized as both a dermatological and systemic disease due to its association with arthritis, cardiovascular disease, and metabolic syndrome.
The global psoriasis vulgaris…
Major Growth Driver Identified in 2025 Psoriasis Market: Prevalence Of Psoriasis …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Psoriasis Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
In recent times, the size of the psoriasis market has experienced a significant increase. It is projected to escalate from $26.56 billion in 2024 to $29.5 billion in 2025, reflecting a compound annual growth rate (CAGR)…
Prevalence Of Psoriasis Driving Market Growth: Key Factor Driving The Growth In …
The Psoriasis Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected Psoriasis Market Size During the Forecast Period?
The psoriasis market has seen rapid growth in recent years. It will increase from $26.56 billion in 2024 to $29.5 billion in 2025, at a…
Plaque Psoriasis to Hold 85% Share of Psoriasis Drugs Market through 2031
Psoriasis is a chronic inflammatory skin disease that occurs due to genetic disposition and environmental factors. Psoriasis is a systemic disease associated with psychological, metabolic, arthritic, and cardiovascular comorbidities. On an average, psoriasis affects around 2 - 3% of the population globally.
Plaque psoriasis, being the number one and most common indication, held nearly 85% share of the US$ 11.37 Bn psoriasis drugs market in 2021, with the market estimated to…
Global Psoriasis Market with Focus on Plaque Psoriasis: Outlook to 2020
Psoriasis is a chronic inflammatory skin disease primarily causing scaling and inflammation of skin, characterized by sharply demarcated, scaly, red skin lesions most often on the elbows, knees, scalps, hands and feet. It occurs when the body’s immune system sends out faulty signals that speed up the growth cycle of skin cells. Psoriasis has been majorly classified into Plaque psoriasis, Guttate psoriasis, Inverse psoriasis, Pustular psoriasis and Erytherodermic psoriasis. It…
